The global drug eluting stent market size was estimated at USD 4.0 billion in 2025 and is projected to reach USD 6.7 billion by 2033, growing at a CAGR of 6.7% from 2026 to 2033. The market is experiencing strong growth due to the rising prevalence of cardiovascular diseases (CVDs), increasing adoption of minimally invasive cardiac procedures, and continuous advancements in interventional cardiology technologies.

Drug eluting stents (DES) have become a critical solution in the treatment of coronary artery disease because they help prevent restenosis by slowly releasing medication into blocked arteries after angioplasty procedures. Increasing incidences of obesity, hypertension, diabetes, sedentary lifestyles, smoking, and unhealthy dietary habits are significantly contributing to the growing burden of cardiovascular disorders globally.

According to the CDC, cardiovascular disease caused 919,032 deaths in the U.S. in 2023, while coronary heart disease accounted for 371,506 deaths. Approximately 805,000 heart attacks occurred nationwide, including 605,000 first-time heart attacks. These statistics highlight the growing need for advanced interventional treatments such as drug eluting stents.

Rising Prevalence of Cardiovascular Diseases and Associated Risk Factors

The increasing prevalence of cardiovascular diseases remains one of the primary drivers of the global drug eluting stent market.

Major contributing risk factors include:

• Obesity
• Hypertension
• Diabetes
• Sedentary lifestyles
• Tobacco consumption
• Aging populations
• Poor dietary habits

The growing number of patients diagnosed with coronary artery disease, heart failure, and peripheral artery disease is significantly increasing demand for minimally invasive procedures such as percutaneous coronary intervention (PCI), angioplasty, and catheter-based therapies.

In December 2025, the CDC released updated obesity prevalence data across all U.S. states and territories. Obesity rates ranged from 25% to over 40%, emphasizing the urgent need for preventive healthcare and cardiovascular treatment strategies.

As the global elderly population continues to expand, healthcare systems are witnessing rising demand for advanced cardiac care solutions capable of improving long-term patient outcomes while reducing hospitalization risks.

Download a free sample copy of the drug eluting stent market report to understand detailed coverage and inclusions in the final report

Key Market Trends & Insights

North America Dominated the Global Market in 2025

The North America drug eluting stents market accounted for the largest global revenue share of 44.1% in 2025.

The region benefits from:

• Advanced healthcare infrastructure
• High awareness of interventional cardiology procedures
• Strong reimbursement systems
• Presence of leading medical device manufacturers
• Increasing adoption of minimally invasive surgeries

Hospitals and specialty cardiac centers across the U.S. and Canada are increasingly performing PCI procedures due to growing awareness regarding early diagnosis and timely intervention for cardiovascular diseases.

Manufacturers are also heavily investing in product innovation and regulatory approvals to strengthen their competitive position within the region.

U.S. Market Witnessing Significant Procedure Volumes

The U.S. drug eluting stents market represented the largest share within North America in 2025.

According to Michigan Medicine, more than 500,000 Americans undergo PCI procedures annually, highlighting the substantial addressable patient pool for drug eluting stent technologies.

The increasing focus on preventive cardiology, early screening programs, and rapid emergency cardiac interventions is contributing to higher procedural volumes across hospitals and outpatient facilities.

Additionally, the rising integration of AI-assisted imaging systems and robotic-assisted PCI technologies is improving procedural accuracy and supporting the adoption of advanced DES products.

Polymer-Based Coating Segment Led the Market

Based on the type of coating, the polymer-based coating segment accounted for the largest revenue share of over 82.8% in 2025.

Polymer-based coatings are widely preferred because they provide:

• Controlled drug release
• Sustained therapeutic effects
• Reduced restenosis rates
• Improved arterial healing
• Better long-term clinical outcomes

Continuous advancements in biocompatible and biodegradable polymer technologies are further improving stent safety and reducing inflammation risks associated with earlier-generation stent platforms.

Manufacturers are increasingly focusing on next-generation polymer technologies designed to optimize vascular healing while minimizing thrombosis complications.

Looking for more specific insights? Customize this report to suite your business needs

Hospitals Segment Dominated by End Use

By end use, the hospitals segment held the largest revenue share of 68.3% in 2025.

The dominance of hospitals is primarily driven by:

• High PCI procedure volumes
• Availability of advanced catheterization laboratories
• Presence of skilled interventional cardiologists
• Emergency cardiac care infrastructure
• Better post-operative monitoring facilities

Hospitals remain the primary treatment centers for acute coronary syndromes and complex cardiovascular interventions requiring advanced imaging and specialized procedural support.

Market Size & Forecast

• 2025 Market Size: USD 4.0 Billion
• 2033 Projected Market Size: USD 6.7 Billion
• CAGR (2026-2033): 6.7%
• North America: Largest market in 2025
• Asia Pacific: Fastest-growing market

Emerging Innovations Transforming the Drug Eluting Stent Industry

The market is witnessing rapid technological advancements focused on improving patient safety, procedural efficiency, and long-term clinical performance.

Emerging innovations include:

• Biodegradable polymer-coated stents
• Bioresorbable vascular scaffolds
• Ultra-thin strut stent technologies
• AI-assisted PCI imaging systems
• Drug-coated balloon combinations
• Precision-guided interventional cardiology platforms

The increasing focus on personalized cardiovascular treatment approaches is encouraging manufacturers to develop advanced DES technologies capable of reducing complications and improving patient-specific treatment outcomes.

Additionally, healthcare providers are increasingly prioritizing minimally invasive procedures due to shorter recovery times, reduced hospital stays, and lower procedural risks compared to traditional surgical interventions.

Explore Grand View Horizon to see global and regional level statistics related to the drug eluting stent market

Competitive Landscape & Company Insights

The global drug eluting stent market is highly competitive, with leading players focusing heavily on innovation, strategic partnerships, geographic expansion, and product commercialization.

Major companies are actively investing in:

• Research and development activities
• Next-generation DES platforms
• Regulatory approvals
• Mergers and acquisitions
• Distribution partnerships
• Emerging market expansion

The growing emphasis on technologically advanced and clinically efficient stent systems is intensifying competition among global medical device manufacturers.

Key Drug Eluting Stent Companies

The following companies have been profiled in the drug eluting stent market:

• Boston Scientific Corporation
• Medtronic
• Abbott
• Teleflex Incorporated
• Terumo Corporation
• B. Braun SE
• Translumina
• MicroPort Scientific Corporation
• Biosensors International Group, Ltd
• Lepu Medical
• iVascular S.L.U.
• SMT
• Meril Life Sciences Pvt. Ltd.
• Concept Medical
• Cardionovum GmbH

Conclusion

The global drug eluting stent market is expected to witness substantial growth through 2033 due to the increasing burden of cardiovascular diseases, rising adoption of minimally invasive cardiac procedures, and continuous technological advancements in interventional cardiology.

Growing prevalence of obesity, diabetes, hypertension, and aging populations continues to increase demand for advanced coronary intervention technologies worldwide. At the same time, innovations in biodegradable polymers, bioresorbable scaffolds, AI-assisted imaging systems, and next-generation DES platforms are transforming the competitive landscape.

As healthcare systems increasingly prioritize early diagnosis, preventive cardiology, and improved long-term patient outcomes, drug eluting stents are expected to remain a critical component of modern cardiovascular treatment strategies globally.

Looking for a report customized to your requirements? Explore our Custom Research Offering

Grand View Research offers

• Focused market intelligence reports on specific geographies or high-growth segments.
• Extended forecast timelines for long-term planning.
• Competitor Benchmarking and Supply Chain Analysis
• Inclusion of regulatory and policy assessments.
• Inclusion of custom data models, KPIs, or applications unique to your business
• Specific high-impact Data Decks and Tables to support effective decision making

And much more…